This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop smallmolecule therapeutics to target RNA processing.
This article compiles recent high-profile clinical readouts and related news with smallmolecules of general interest and structures where they are available. Unlike sapropterin, sepiapterin is more active in cells and is also brain-penetrant.
The majority of smallmolecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.
This laid the groundwork for my career in drug discovery using novel modalities like smallmolecule inhibitors, antibodies, RNA interference (RNAi) and, currently, smallmolecule protein degraders – which are opportunities to change how we think about medicines.
Haemoglobin A1c (HbA1c) is a validated surrogate endpoint for the reduction of microvascular complications associated with diabetes mellitus; reduced HIV-RNA levels serve as an endpoint for HIV disease control; and a reduction in low-density lipoprotein (LDL) cholesterol is used as an endpoint indicating lower likelihood of cardiovascular events.
The researchers also looked at the tool’s ability to detect changes in cellular phenotypes after exposure to drugs and smallmolecule compounds. That teaches us far more than looking for just a single informative data point.” Typically, studying drug therapies is an expensive and time-consuming undertaking.
” The report accompanies an article in Science , also released today, entitled “Confronting Risks of Mirror Life.” For the article in Science , more than 30 scientists from ten countries are calling on the broader community to confront the risks of mirrored life. ” But what, exactly, is a mirrored organism?
In this article, I spoke to Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, about how AI is transforming the landscape of disease research, unlocking a treasure trove of knowledge that may hold the key to a healthier future. Cavlan will explore more of these ends in our next article.
This is Codon Digest, a weekly roundup of research papers, news articles, and industry highlights about engineered biology. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). Massively parallel profiling of RNA-targeting CRISPR-Cas13d.
In this blog article, we review some of these areas of investigation where Altasciences has robust expertise and solution offerings. According to a 2022 article published in Molecular Psychiatry, treatment resistance affects 20 to 60% of patients with psychiatric disorders. Asia, and Europe.
Sign up to get articles from Asimov Press. Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. As the DNA passed through a nanopore, these hairpins would get stuck inside the nanopore and slow down the DNA’s movement.
Read Ribosomes are able to build proteins because they contain a strand of RNA that imbues them with their catalytic power. Read An automated platform to make riboswitches (RNA strands that bind to smallmolecules and then quickly switch their structure) that can sense specific proteins. Synthetic Biology. Cell Systems.
Read Ribosomes are able to build proteins because they contain a strand of RNA that imbues them with their catalytic power. Read An automated platform to make riboswitches (RNA strands that bind to smallmolecules and then quickly switch their structure) that can sense specific proteins. Synthetic Biology. Cell Systems.
Susannah’s ASO Treatment Regimen A brief note: Throughout this post I will be citing the original article; unless otherwise noted, quotes are sourced from Ziegler et al. The effects of an ASO administered to the eye have yet to be determined, and we are also investigating small-molecule therapies to treat this high-priority symptom.
Read There’s a news article that breaks down this work. Read An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Read [Comment] Delivering the next generation of cancer immunotherapies with RNA. Comparison of transformations for single-cell RNA-seq data. Favate J.S. Debès C.
This article is best experienced on our website. Building a Circuit Much like electronic circuits, which use wires and transistors to create or process signals, a synthetic gene circuit is a network of biological parts — DNA, RNA, and proteins — that process inputs and generate outputs. 3 Subscribe to Asimov Press.
In this article, we spoke with Fiona Elwood, PhD, Vice President and Disease Area Stronghold Leader for Neurodegeneration at Johnson & Johnson. Were diversifying our portfolio beyond tau to other targets and molecules that could be dosed alone or even in the future as part of combinations, Elwood reveals.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content